MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, May 9, 2024, at 4:30 pm ET.
馬里蘭州羅克維爾，2024年5月3日（環球新聞專線）——專注於開發、製造和商業化治療癌症的創新抗體療法的生物製藥公司MacroGenics, Inc.（納斯達克股票代碼：MGNX）今天宣佈，該公司將在2024年5月9日星期四收盤後發佈2024年第一季度的財務業績。MacroGenics將於美國東部時間2024年5月9日星期四下午4點30分主持電話會議，討論財務業績和最近的公司進展。
Conference Call Information
電話會議信息
To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.
要通過電話參加，請提前在此處註冊 鏈接。註冊後，所有電話參與者都將收到一封確認電子郵件，詳細說明如何加入電話會議，包括撥入號碼以及可用於接聽電話的唯一密碼和註冊人ID。本次電話會議的僅限收聽的網絡直播可在公司網站投資者關係部分的 “活動與演講” 下觀看 http://ir.macrogenics.com/events.cfm。電話會議結束後不久將提供網絡直播的錄製重播，並在電話會議結束後的30天內在公司網站上存檔。
About MacroGenics, Inc.
關於 MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
MacroGenics（以下簡稱 “公司”）是一家生物製藥公司，專注於開發、製造和商業化用於治療癌症的基於單克隆抗體的創新療法。該公司主要從其專有的下一代抗體技術平台套件中生成候選產品線，這些平台適用於廣泛的治療領域。MacroGenics的技術平台和蛋白質工程專業知識相結合，使公司能夠開發出有前途的候選產品，並與全球製藥和生物技術公司進行多項戰略合作。欲了解更多信息，請訪問公司的網站 wwwmacrogenics.com。MacroGenics 和 MacroGenics 徽標是 MacroGenics, Inc. 的商標或註冊商標。
###
###
CONTACTS: Jim Karrels, Senior Vice President, CFO 1-301-251-5172, info@macrogenics.com
聯繫人：吉姆·卡雷爾斯，高級副總裁，首席財務官1-301-251-5172， info@macrogenics.com
Source: MacroGenics, Inc.
資料來源：MacroGenics, Inc.
譯文內容由第三人軟體翻譯。